Q203, a drug candidate to treat MDR-tuberculosis, was designated as an 'orphan drug' by the FDA while on clinical trials.  According to the 1938 Orphan Drug Act, there are many benefits placed on orphan drugs including tax incentives, enhanced patent protection and marketing rights, clinical research financial subsidization, etc. Qurient licensed Q203 from Institut Pasteur Korea and has ushered it through the process - candidate selection, patent, drug efficacy evaluation, non-clinical development and clinical trial phase 1.


Source: Medical News (28 December, 2015)